Pan Tumor Rollover Study
Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.
| Condition(s) | Cancer |
|---|---|
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Summary | Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types. |
| Who can participate | Inclusion Criteria * Signed Written Informed Consent. * Eligible to receive continued study treatment per the Parent Study, including treatment beyond progression per investigator assessment in the Parent Study. * On treatment hold in the Parent Study following long-lasting response or are eligible for treatment rechallenge as defined in the Parent Study. * WOCBP and male participants who are sexually active must agree to follow instructions for method(s) of contraception as described below and included in the ICF. Exclusion Criteria * Participant is not eligible for study treatment per the Parent Study eligibility criteria. * Participants not receiving clinical benefit as assessed by the Investigator. * Any clinical adverse event (AE), laboratory abnormality, or intercurrent illness which |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Bristol-Myers Squibb |
| Locations | Huntsville, Alabama, United States; Tucson, Arizona, United States; Lynwood, California, United States; San Francisco, California, United States; San Francisco, California, United States; Aurora, Colorado, United States (+393 more sites) |
| Start date | 2019-08-09 |
| NCT ID | NCT03899155 |
| Official listing | https://clinicaltrials.gov/study/NCT03899155 |